Literature DB >> 11159212

A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake.

L Kölby1, P Bernhardt, H Ahlman, B Wängberg, V Johanson, A Wigander, E Forssell-Aronsson, S Karlsson, B Ahrén, G Stenman, O Nilsson.   

Abstract

A human midgut carcinoid tumor was successfully transplanted into nude mice and propagated for five consecutive generations (30 months) with well-preserved phenotype. Tumor cells in nude mice expressed identical neuroendocrine markers as the original tumor, including somatostatin receptors (somatostatin receptors 1 to 5) and vesicular monoamine transporters (VMAT1 and VMAT2). Because of the expression of somatostatin receptors and VMAT1 and VMAT2 the grafted tumors could be visualized scintigraphically using the somatostatin analogue 111In-octreotide and the catecholamine analogue 123I-metaiodobenzylguanidine. The biokinetics of the somatostatin analogue 111In-octreotide in the tumors was studied and showed a high retention 7 days after administration. Cell cultures were re-established from transplanted tumors. Immunocytochemical and ultrastructural studies confirmed the neuroendocrine differentiation. The human origin of transplanted tumor cells was confirmed by cytogenetic and fluorescence it situ hybridization analyses. Spontaneous secretion of serotonin and its metabolite, 5-hydroxyindole acetic acid, from tumor cells was demonstrated. The tumor cells increased their [Ca2+]i in response to beta-adrenoceptor stimulation (isoproterenol) and K+-depolarization. All somatostatin receptor subtypes could be demonstrated in cultured cells. This human transplantable carcinoid tumor, designated GOT1, grafted to nude mice, will give unique possibilities for studies of somatostatin receptor- and VMAT-mediated radionuclide uptake as well as for studies of secretory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159212      PMCID: PMC1850312          DOI: 10.1016/S0002-9440(10)64017-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  Cytosolic Ca2+ oscillations by gastrin releasing peptide in single HIT-T15 cells.

Authors:  S Karlsson; B Ahrén
Journal:  Peptides       Date:  1999       Impact factor: 3.750

2.  Production of transferable neuronotrophic factor(s) by human midgut carcinoid tumour cells; studies using cultures of rat fetal cholinergic neurons.

Authors:  A Wigander; K Lundmark; A McRae; J Mölne; O Nilsson; K Haglid; A Dahlström; H Ahlman
Journal:  Acta Physiol Scand       Date:  1991-01

3.  Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I).

Authors:  R Pfragner; G Wirnsberger; B Niederle; A Behmel; I Rinner; A Mandl; F Wawrina; J Luo; D Adamiker; H Hoger; E Ingolic; K Schauenstein
Journal:  Int J Oncol       Date:  1996-03       Impact factor: 5.650

4.  Electrophysiological properties of human carcinoid cells of the gut.

Authors:  G Glassmeier; C Strübing; E O Riecken; H Buhr; P Neuhaus; G Ahnert-Hilger; B Wiedenmann; H Scherübl
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

Review 5.  The catecholamine transporter of adrenal medulla chromaffin granules.

Authors:  J P Henry; B Gasnier; C Desnos; D Scherman; E Krejci; J Massoulié
Journal:  Ann N Y Acad Sci       Date:  1994-09-15       Impact factor: 5.691

6.  Secretory patterns of tryptophan metabolites in midgut carcinoid tumor cells.

Authors:  G Westberg; H Ahlman; O Nilsson; A Illerskog; B Wängberg
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

7.  The role of Ca2+ in the release of pancreatic islet hormones.

Authors:  B Hellman; E Gylfe; P Bergsten; E Grapengiesser; P E Lund; A Berts; S Dryselius; A Tengholm; Y J Liu; M Eberhardson
Journal:  Diabete Metab       Date:  1994 Mar-Apr

8.  Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?

Authors:  O Nilsson; B Wängberg; E Theodorsson; A Skottner; H Ahlman
Journal:  Int J Cancer       Date:  1992-05-08       Impact factor: 7.396

9.  Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.

Authors:  M Fjälling; P Andersson; E Forssell-Aronsson; J Grétarsdóttir; V Johansson; L E Tisell; B Wängberg; O Nilsson; G Berg; A Michanek; G Lindstedt; H Ahlman
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

10.  Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.

Authors:  O Nilsson; L Kölby; B Wängberg; A Wigander; H Billig; L William-Olsson; M Fjälling; E Forssell-Aronsson; H Ahlman
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

View more
  35 in total

Review 1.  Mechanisms of storage and exocytosis in neuroendocrine tumors.

Authors:  Manfred Gratzl; Martin Breckner; Christian Prinz
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

2.  Recombinant α1-Microglobulin Is a Potential Kidney Protector in 177Lu-Octreotate Treatment of Neuroendocrine Tumors.

Authors:  Charlotte K Andersson; Emman Shubbar; Emil Schüler; Bo Åkerström; Magnus Gram; Eva B Forssell-Aronsson
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

3.  Interaction of Human Enterochromaffin Cells with Human Enteric Adenovirus 41 Leads to Serotonin Release and Subsequent Activation of Enteric Glia Cells.

Authors:  Sonja Westerberg; Marie Hagbom; Anandi Rajan; Vesa Loitto; B David Persson; Annika Allard; Johan Nordgren; Sumit Sharma; Karl-Eric Magnusson; Niklas Arnberg; Lennart Svensson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

4.  Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice.

Authors:  Jenny Oddstig; Peter Bernhardt; Helena Lizana; Ola Nilsson; Håkan Ahlman; Lars Kölby; Eva Forssell-Aronsson
Journal:  Tumour Biol       Date:  2011-11-23

5.  Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.

Authors:  Matilde Spampatti; George Vlotides; Gerald Spöttl; Julian Maurer; Burkhard Göke; Christoph J Auernhammer
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  Translational research in neuroendocrine tumors: pitfalls and opportunities.

Authors:  J Capdevila; O Casanovas; R Salazar; D Castellano; A Segura; P Fuster; J Aller; R García-Carbonero; P Jimenez-Fonseca; E Grande; J P Castaño
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

7.  Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.

Authors:  Ellinor Andersson; Yvonne Arvidsson; Christina Swärd; Tobias Hofving; Bo Wängberg; Erik Kristiansson; Ola Nilsson
Journal:  Mod Pathol       Date:  2016-03-11       Impact factor: 7.842

8.  Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease.

Authors:  M Friedrich; J Diegelmann; J Schauber; C J Auernhammer; S Brand
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

9.  [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney.

Authors:  Christina Swärd; Peter Bernhardt; Håkan Ahlman; Bo Wängberg; Eva Forssell-Aronsson; Maria Larsson; Johanna Svensson; Rauni Rossi-Norrlund; Lars Kölby
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

10.  Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids.

Authors:  Po Hien Ear; Guiying Li; Meng Wu; Ellen Abusada; Andrew M Bellizzi; James R Howe
Journal:  J Vis Exp       Date:  2019-10-14       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.